CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy. Trials currently under CCTG's DSMC oversight include:
Join us in welcoming a new patient representative, Tracey Kitz who will be supporting the Hematology Committee.
Tracy Kitz is an optometrist living in Edmonton, Alberta, who dedicates herself to understanding and meeting the needs of her patients every day. In 2009, her mother was diagnosed with multiple myeloma and underwent surgery, chemotherapy, and radiation, followed by a stem cell transplant in 2014.
The CCTG MA.40 (FINER) clinical trial, is a double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER-2 negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor.
In a world-first clinical trial, researchers working with the Canadian Cancer Trials Group (CCTG) have demonstrated that a structured exercise program significantly improves survival for colon cancer patients by reducing the risk of disease recurrence and new primary cancers.
The ASCO 2025 Annual Meeting, is fast approaching and will be held from May 30 to June 3 in Chicago, Illinois -- This year the theme is of "Driving Knowledge to Action: Building a Better Future". This meeting will feature many CCTG trials and research so please see the list below to ensure you do not miss the oral presentations or poster presentations, showcasing the latest in CCTG research and clinical trial results.
